Conference Reports for NATAP

9th International Congress on Drug Therapy in HIV Infection Glasgow November 9-13, 2008 Back

Efficacy and safety of switching from Lopinavir/r to Atazanavir/r in suppressed patients receiving a LPV/r containing HAART: ATAZIP 96 weeks results       Reported by Jules Levin Ninth International Congress on Drug Therapy in HIV Infection 09-13 November 2008 Glasgow, UK   Mallolas J.1, Podzamczer D.2, Domingo P.3, Echevarria P.4, Ribera E.5, Gutierrez F.6, Knobel H.7, Cosin J.8, Ferrer E.2, Arranz J.A.9, Roca V.10, Pich J.11, de Lazzari E.12, Gatell J.M.1, for the ATAZIP study group   Background   ATV is a potent, well-tolerated, once-daily (QD) protease inhibitor (PI) extensively studied in treatment-naive and -experienced patients   The SWAN study (BMS 097)1demonstrated that switching from PI ± RTV-containing regimens to an unboostedATV-containing regimen maintained virologic suppression with improvement in plasma lipids through 48 weeksin patients without previous failures to PI contaningregimens   One year outcomes provided comparable efficacy and safety profiles between study arms with improved lipid parameters in patients switching to ATV/r2   1Gatell et al. Clin Infect Dis 2007 2Mallolas et al. IAS 2007, Sydney   Objective   To assess the safety and efficacy of ATV/r based HAART in virologically suppressed patients receiving a LPV/r contaningregimen including patients with previous failures (< 3) to PI regimens or history of having PI associated mutations (< 5) prior to starting the LPV/r-based regimen.   Primary end-point   The proportion of patients with treatment failure for any reason through Week 48Includes virologic rebound (> 200 cp/mL), discontinuation of study therapy or lost to follow- up, progression to a new CDC event or death.   Non-inferiority study. Upper limit of 95% CI of estimated difference < 12.5% Secondary end-points   The proportion of patients with virologic rebound at Week 48 and at Week 96 --Confirmed on-study HIV RNA ≥ 200 copies/mL or last on-study HIV RNA ≥ 200 copies/mL followed by discontinuation   Time to treatment failure and to virologicfailure at Week 96   Safety   Evolution of fasting plasma lipids   Conclusions   Switching to ATV/r in virologicallysuppressed patients who were receiving a LPV/r containing HAART provided durable and comparable efficacy outcomes, no unexpected safety events and improved lipid parameters